4-methoxy-N,3-dimethylaniline | 124959-20-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-methoxy-N,3-dimethylaniline
• CAS: 124959-20-2
• 化学式: C₉H₁₃NO
• 分子量: 151.208
• InChiKey: UHJGLJYAQURFLE-UHFFFAOYSA-N

物化性质

• 沸点：
  247.6±28.0 °C(Predicted)
• 密度：
  1.013±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-methoxy-N,3-dimethylaniline 在 三乙烯二胺 、 N-氯代丁二酰亚胺 、 二苯醚 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 77.0h， 生成 2-methoxy-5-methyl-3-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-indolo [2,3-b]quinoline-8-carbonitrile
  参考文献：
  名称：

  [EN] INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS
  [FR] COMPOSÉS D'INDOLOQUINOLONE UTILISÉS EN TANT QU'INHIBITEURS DE KINASE DU LYMPHOME ANAPLASIQUE (ALK)

  摘要：

  公开了某些吲哚喹诺酮化合物、其制备方法、药物组合物及其用途，例如用作ALK抑制剂。

  公开号：

  WO2015127629A1
• 作为产物：
  描述：

  2-甲基苯甲醚 、 N-methyl-O-tosylhydroxylamine 在 air 作用下， 反应 36.0h， 以53%的产率得到4-methoxy-N,3-dimethylaniline
  参考文献：
  名称：

  无金属直接芳烃 C−H 胺化

  摘要：

  通过形成 CN 键合成芳胺是制备功能材料、活性药物成分和生物活性产品的重要工具。通常，这种化学连接只能通过过渡金属催化的反应、光化学或电化学来实现。在这里，我们报告了在良性条件下使用羟胺衍生物进行的无金属芳烃 C-H 胺化。即使在存在各种官能团的情况下，胺化试剂 TsONHR 和芳烃底物之间的电荷转移相互作用也能实现芳烃的化学选择性胺化。氧气对于有效转化至关重要，其对电子转移步骤的加速作用已通过实验证明。此外，

  DOI：

  10.1002/adsc.202100236

文献信息

• Amination of Arenes with<i>N</i>,<i>N</i>-Dimethyl-2-imidazolidinone<i>O</i>-Methoxyacetyloxime
  作者：Nicolas Baldovini、Mitsuru Kitamura、Koichi Narasaka

  DOI：10.1246/cl.2003.548

  日期：2003.6

  Treatment of nucleophilic arenes with N,N-dimethyl-2-imidazolidinone O-methoxyacetyloxime and SnCl4 produced the corresponding N-arylimines, which were converted to anilines by hydrolysis with CsOH and to N-methylanilines by LiAlH4 reduction.

  使用N,N-二甲基-2-咪唑啉酮O-甲氧基乙酰肟和SnCl4处理亲核芳香烃，生成了相应的N-芳基亚胺，通过与CsOH水解转化为苯胺，或通过LiAlH4还原转化为N-甲基苯胺。
• Coupling compounds and hair dyeing compositions containing them
  申请人：DyStar Textilfarben GmbH & Co. Deutschland KG

  公开号：EP1847528A1

  公开（公告）日：2007-10-24

  The present invention refers to compounds of the formula (I) wherein R1 is (C1-C4)-alkyl, (C1-C4)-alkyl which is substituted by hydroxy, (C1-C4)-alkoxy, hydroxy-(C1-C4)-alkoxy, CN, -COOR5, -CON(R5)2 or -N(R5)2 or is phenyl; R2 is hydrogen, methyl or ethyl; R3 is (C1-C4)-alkylsulfonyl, (C1-C4)-alkylsulfonyl which is substituted by hydroxy, halogen, cyano, (C1-C4)-alkoxy or -N(R5)2 or is -SO2-CH=CH2, -SO2N(R5)2 or -PO(OR5)2; R4 is hydrogen, (C2-C4)-alkyl which is substituted by hydroxy, (C1-C4)-alkoxy or hydroxy-(C1-C4)-alkoxy; each of R5, independently is hydrogen, (C1-C4)-alkyl or hydroxy-(C2-C4)-alkyl; whereas R3 is not -NHSO2CH3 if R2 and R4 are both hydrogen and R1 is methyl, as well as hair dye compostions containing them.

  本发明涉及以下式(I)的化合物其中R1是(C1-C4)-烷基，被羟基取代的(C1-C4)-烷基，(C1-C4)-氧烷基，羟基-(C1-C4)-氧烷基，CN，-COOR5，-CON(R5)2或-N(R5)2或是苯基；R2是氢，甲基或乙基；R3是(C1-C4)-烷基磺酰基，被羟基，卤素，氰基，(C1-C4)-氧烷基或-N(R5)2取代的(C1-C4)-烷基磺酰基，或是-SO2-CH=CH2，-SO2N(R5)2或-PO(OR5)2；R4是氢，被羟基，(C1-C4)-氧烷基或羟基-(C1-C4)-氧烷基取代的(C2-C4)-烷基；R5中的每一个独立地是氢，(C1-C4)-烷基或羟基-(C2-C4)-烷基；其中如果R2和R4都是氢且R1是甲基，则R3不是-NHSO2CH3，以及含有它们的染发组合物。
• Structure based drug design and in vitro metabolism study: Discovery of N-(4-methylthiophenyl)-N,2-dimethyl-cyclopenta[d]pyrimidine as a potent microtubule targeting agent
  作者：Weiguo Xiang、Shruti Choudhary、Ernest Hamel、Susan L. Mooberry、Aleem Gangjee

  DOI：10.1016/j.bmc.2018.04.010

  日期：2018.5

  We report a series of tubulin targeting agents, some of which demonstrate potent antiproliferative activities. These analogs were designed to optimize the antiproliferative activity of 1 by varying the heteroatom substituent at the 4'-position, the basicity of the 4-position amino moiety, and conformational restriction. The potential metabolites of the active compounds were also synthesized. Some compounds

  我们报告了一系列的微管蛋白靶向剂，其中一些表现出有效的抗增殖活性。这些类似物的设计旨在通过改变4'-位的杂原子取代基，4-位氨基部分的碱性和构象限制条件来优化1的抗增殖活性。还合成了活性化合物的潜在代谢产物。一些化合物在MDA-MB-435黑色素瘤细胞中显示出抗增殖作用的一位数纳摩尔IC50值。特别是，在MDA-MB-435细胞中，S-甲基类似物3比1更有效（IC50 = 4.6 nM）。与人肝微粒体一起孵育3，表明3的S-甲基部分的主要代谢产物是甲基亚磺酰基，与类似物5一样。该代谢产物在MDA-MB-435细胞中与先导化合物1等价（IC50 = 7。9 nM）。确定分子模型和静电表面积以解释类似物的活性。大多数有效的化合物克服了多种耐药性机制，化合物3作为进一步SAR和临床前开发的先导化合物而出现。
• Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents
  申请人：Duquesne University of the Holy Spirit

  公开号：US20160304525A1

  公开（公告）日：2016-10-20

  The present invention provides a compound of Formula I, and salts thereof, and a pharmaceutical composition comprising a compound of Formula I: wherein R 1 is selected from the group consisting of and R 2 is an alkyl group having from one to ten carbon atoms, or wherein R 2 is selected from the group consisting of R 1 is an alkyl group having from one to ten carbon atoms; and R is H, or an alkyl group having from one to ten carbon atoms, and R 3 is H, an alkyl group having from one to ten carbon atoms, or a halogen. Preferably the compound of Formula V includes wherein R 3 is a halogen, and most preferably wherein the halogen is chlorine. Methods of treating a patient with cancer with these compounds are also provided.

  本发明提供了一种化合物I的盐，以及包括化合物I的药物组合物：其中R1选自以下组成的群体，R2是具有一到十个碳原子的烷基基团，或者R2选自以下组成的群体，R1是具有一到十个碳原子的烷基基团；R是H，或者具有一到十个碳原子的烷基基团，R3是H，具有一到十个碳原子的烷基基团，或者卤素。优选化合物V包括其中R3是卤素，最优选其中卤素是氯。还提供了使用这些化合物治疗癌症患者的方法。
• Quinolone sulphonates having antihypertensive activity
  申请人：The Boots Company, PLC

  公开号：US04997840A1

  公开（公告）日：1991-03-05

  Quinolone sulphonates of formula I ##STR1## in which R.sub.1 is lower alkyl; R.sub.2 is lower alkyl; and R.sub.3, R.sub.4 and R.sub.5, which may be the same or different, are hydrogen, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, halo, halogenated lower alkyl, halogenated lower alkoxy, cyano, phenyl or phenyl substituted by 1 or 2 groups independently selected from lower alkyl, lower alkoxy and halo, have antihypertensive activity. Processes for preparing compounds of formula I and pharmaceutical compositions containing them are described. Compounds of formula I are also indicated for use in the treatment of heart failure and ischaemic heart disease.

  化学式I的喹诺酮磺酸盐：##STR1## 其中，R.sub.1为低碳基；R.sub.2为低碳基；R.sub.3、R.sub.4和R.sub.5可以相同也可以不同，分别为氢、低碳基、低氧基、低硫基、低硫氧基、低硫酰基、卤素、卤素化的低碳基、卤素化的低氧基、氰基、苯基或由1或2个从低碳基、低氧基和卤素中独立选择的基取代的苯基。这些化合物具有降压作用。本文还描述了制备化学式I化合物和含有它们的药物组合物的方法。化学式I的化合物也适用于治疗心力衰竭和缺血性心脏病。